Renal Cell Carcinoma - Pipeline Review, Q1 2011 by GlobalMarketsDirect

VIEWS: 1 PAGES: 82

Renal Cell Carcinoma - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Renal Cell Carcinoma - Pipeline Review, Q1 2011', provides an overview of the Renal Cell Carcinoma therapeutic pipeline. This report provides information on the therapeutic development for Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma. 'Renal Cell Carcinoma - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Renal Cell Carcinoma.
- A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Renal Cell Carcinoma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effecti

More Info
									          Renal Cell Carcinoma - Pipeline Review, Q1 2011
                                                                                          Reference Code: GMDHC443IDB

                                                                                          Publication Date: January 2011




Renal Cell Carcinoma – Pipeline Review, Q1 2011                                                                       GMDHC443IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                                         Page(1)
Renal Cell Carcinoma – Pipeline Review, Q1 2011




Ta b le o f Co n te n ts
Table of Contents                                                                                              2
List of Tables                                                                                                 5
List of Figures                                                                                                6
Introduction                                                                                                   7
     Global Markets Direct Report Coverage                                                                     7
Renal Cell Carcinoma Overview                                                                                  8
Therapeutics Development                                                                                       9
     An Overview of Pipeline Products for Renal Cell Carcinoma                                                 9
Renal Cell Carcinoma Therapeutics under Development by Companies                                              11
Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes                              14
Late Stage Products                                                                                           20
     Comparative Analysis                                                                                     20
Mid Clinical Stage Products                                                                                   21
     Comparative Analysis                                                                                     21
Early Clinical Stage Products                                                                                 22
     Comparative Analysis                                                                                     22
Pre-Clinical Stage Products                                                                                   23
     Comparative Analysis                                                                                     23
Companies Involved in Renal Cell Carcinoma Therapeutics Development                                           24
     Bristol-Myers Squibb Company                                                                             24
     Johnson & Johnson                                                                                        24
     Abbott Laboratories                                                                                      25
     AstraZeneca PLC                                                                                          25
     Eli Lilly and Company                                                                                    26
     GlaxoSmithKline plc                                                                                      26
     Seattle Genetics, Inc.                                                                                   27
     Antigenics, Inc.                                                                                         27
     Merck & Co., Inc.                                                                                        28
     Oxford BioMedica plc                                                                                     28
     Novo Nordisk A/S                                                                                         29
     Novartis AG                                                                                              29
     Astellas Pharma Inc.                                                                                     30
     Eisai Co., Ltd.                                                                                          30
     Pfizer Inc.                                                                                              31
     SuperGen, Inc.                                                                                           31
     Bayer AG                                                                                                 32
     EntreMed, Inc.                                                                                           32
     AEterna Zentaris Inc.                                                                                    33
     Lorus Therapeutics Inc                                                                                   33
     Bionomics Limited                                                                                        34
     Flamel Technologies S.A.                                                                                 34
     MOLOGEN AG                                                                                               35
     Rexahn Pharmaceuticals, Inc.                                                                             35
     Baylor College of Medicine                                                                               36
     immatics biotechnologies GmbH                                                                            36
     Argos Therapeutics, Inc.                                                                                 37
     Cytheris SA                                                                                              37


Renal Cell Carcinoma – Pipeline Review, Q1 2011                                           GMDHC443IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                             Page(2)
Renal Cell Carcinoma – Pipeline Review, Q1 2011


     GenKyoTex S.A.                                                                                           38
     Immutep S.A.                                                                                             38
     AVEO Pharmaceuticals, Inc.                                                                               39
     AstraZeneca AB                                                                                           39
     TenX Biopharma, Inc.                                                                                     40
     Agennix AG                                                                                               40
Universities/Institutes Involved in Renal Cell Carcinoma Therapeutics Development                             41
Renal Cell Carcinoma Therapeutics Assessment                                                                  49
     Assessment by Monotherapy Products                                                                       49
     Assessment by Combination Products                                                                       50
     Assessment by Route of Administration                                                                    51
     Assessment by Molecule Type                                                                              53
Late Stage Drug Profiles – Companies                                                                          55
     Bevacizumab + Torisel - Drug Profile                                                                     55
          Product Description                                                                                 55
          Mechanism of Action                                                                                 55
          R&D Progress                                                                                        55
     Sutent - Drug Profile                                                                                    56
          Product Description                                                                                 56
          Mechanism of Action                                                                                 56
          R&D Progress                                                                                        56
     TroVax - Drug Profile                                                                                    57
          Product Description                                                                                 57
          Mechanism of Action                                                                                 57
          R&D Progress                                                                                        57
     TroVax + IL-2 - Drug Profile                                                                             58
          Product Description                                                                                 58
          Mechanism of Action                                                                                 58
          R&D Progress                                                                                        58
Late Stage Drug Profiles – Universities/Institutes                                                            59
     Aldesleukin + Interferon - Drug Profile                                                                  59
          Product Description                                                                                 59
          Mechanism of Action                                                                                 59
          R&D Progress                                                                                        59
     Aldesleukin for Kidney Cancer - Drug Profile                                                             61
          Product Description                                                                                 61
          Mechanism of Action                                                                                 61
          R&D Progress                                                                                        61
     Interferon Alfa-2B - Drug Profile                                                                        62
          Product Description                                                                                 62
          Mechanism of Action                                                                                 62
          R&D Progress                                                                                        62
     Interferon Alfa-2B + Bevacizumab - Drug Profile                                                          63
          Product Description                                                                                 63
          Mechanism of Action                                                                                 63
          R&D Progress                                                                                        63
     Interferon Alpha-2a + Aldesleukin - Drug Profile                                                         64
          Product Description                                                                                 64




Renal Cell Carcinoma – Pipeline Review, Q1 2011                                           GMDHC443IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                       Page(3)
Renal Cell Carcinoma – Pipeline Review, Q1 2011


          Mechanism of Action                                                                                                                     64
          R&D Progress                                                                                                                            64
     Interferon-alpha - Drug Profile                                                                                                              66
          Product Description                                                                                                                     66
          Mechanism of Action                                                                                                                     66
          R&D Progress                                                                                                                            66
     Interleukin 2 + Interferon-alpha2 - Drug Profile                                                                                             67
          Product Description                                                                                                                     67
          Mechanism of Action                                                                                                                     67
          R&D Progress                                                                                                                            67
     Medroxyprogesterone - Drug Profile                                                                                                           68
          Product Description                                                                                                                     68
          Mechanism of Action                                                                                                                     68
          R&D Progress                                                                                                                            68
     Recombinant Interferon Alpha-2a - Drug Profile                                                                                               69
          Product Description                                                                                                                     69
          Mechanism of Action                                                                                                                     69
          R&D Progress                                                                                                                            69
     sorafenib - Drug Profile                                                                                                                     70
          Product Description                                                                                                                     70
          Mechanism of Action                                                                                                                     70
          R&D Progress                                                                                                                            70
     sorafenib + sunitinib - Drug Profile                                                                                                         71
          Product Description                                                                                                                     71
          Mechanism of Action                                                                                                                     71
          R&D Progress                                                                                                                            71
     Sunitinib - Drug Profile                                                                                                                     72
          Product Description                                                                                                                     72
          Mechanism of Action                                                                                                                     72
          R&D Progress                                                                                                                            72
Discontinued Products                                                                                                                             73
     Renal Cell Carcinoma - Featured News                                                                                                         74
          Nov 19, 2010: Pfizer's Positive Phase III Trial Of Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma Met Primary
          Endpoint                                                                                                                                 74
          Nov 10, 2010: AVEO To Present New Clinical Data Evaluating Tivozanib In Combination With FOLFOX6 At ORTC-NCI-AACR Symposium
                                                                                                                                    74
          Oct 11, 2010: Seattle Genetics Reports Preliminary Data From Phase I Clinical Trial Of SGN-75                                           75
          Oct 04, 2010: Seattle Genetics To Present SGN-75 Clinical Data At European Society For Medical Oncology Congress                        75
          Oct 01, 2010: Argos Therapeutics Announces Encouraging Results From Phase II Combination Study Of AGS-003 In Renal Cell
          Carcinoma                                                                                                                               76
          Oct 01, 2010: AVEO Pharmaceuticals Presents Phase II Study Results Of Tivozanib At International Kidney Cancer Symposium                77
          Oct 01, 2010: AVEO Pharmaceuticals Presents Phase Ib Study Data Of Tivozanib In Combination With Temsirolimus At International
          Kidney Cancer Symposium                                                                                                                 78
          Sep 24, 2010: Argos Presents Results From Arcelis Immunotherapy Phase II Study For Treatment Of Renal Cell Carcinoma At
          International Kidney Cancer Symposium                                                                                                   78
          Jun 24, 2010: AVEO Receives European Orphan Medicinal Product Designation For Tivozanib For Treatment Of Renal Cell Carcinoma 
								
To top